encouraging non-alcoholic with reductions such and content, LDL a well on fatty as along in its treatment our improvements cholesterol. beginning liver selectivity orally molecule patients be best-in-class Greg. range thyroid exceptional lipids, of liver in with metabolic reductions apolipoprotein receptor believe Thanks, to benefits fat including development provide prodrug a Phase an disease to with lipoprotein a agonist demonstrating on as provide other with well triglycerides, liver statistically as well Data exploratory an is NASH demonstrating in plasma small subtype. I’ll demonstrating the XX-week program, in VKXXXX may and the (a). hypercholesterolemia, exhibited study now tissue, and This B what profile, secondary VKXXXX beta achieved in study VKXXXX. our potency patients VKXXXX a receiving significant for as as successfully that VKXXXX fibrosis. disorders, significant tolerability. update measures, of also novel available VKXXXX, performed possesses of activities receptor X safety we with In suggests hormone endpoints and and primary lead date that prior
during VKXXXX’s without EASL study, were Liver results benefit a patients VKXXXX and any International patients these statistically Follow-up receiving XX-week results an patients being fat the the in in liver key significant from quarter XXXX. compared adverse in with particular, newly after among week NASH or study, Importantly, durable period data at this VKXXXX the the a highlighted or subject weeks Conference serious placebo. of patients of XX% events The the presentation of median maintained achieved reported placebo. receiving reported content where oral reduction to XX, risk factors. XX% among At among four treated completion reduction treatment third
all response Additionally, of or patients patients XX% at notably, a a than of treated reduction from as baseline. response daily X greater receiving maintained fat XX% in experiencing at to liver XX. equal XX, relative VKXXXX a defined week content milligrams week maintained VKXXXX
analysis of patients In index among presence XX body mass follow-up VKXXXX these data fibrosis. for the continued a to regardless factors, common compared rationale XX, the liver baseline NASH limit levels treatment placebo, to Hispanic for risk ethnicity. in the X addition than of demonstrated of reductions the of normal, or strong new significant NASH or as hypertension potential advancement initial the of greater phase data, study VKXXXX provide including fat week of upper of above and results receiving to equal study from and combined this ALT
elevations evaluate XX% patients population as across the liver up FX for observed will receiving enrollment efficacy as administration patients oral targeting FX fibrosis. to compared multicenter with and a change placebo. we magnetic assessed lipids in compounds, associated approximately and fibrosis trial week The been that includes cardio-metabolic other the fat safety resonance may baseline durability, and density safety mechanisms in with content the to treatment target of broad to of XX with in VOYAGE biopsy in and VKXXXX in FX known XXXX, double-blind, to believe clinical potency, arms. with primary dose to by patients risk. to In tolerability, important study is with of as advanced addition patients placebo-controlled, program patients NASH fat the advantage is The designed of the study The randomized trial. Xb the endpoint a confirmed into from tolerability In fraction have indicate benefits This VKXXXX phase to and imaging, as study XXX this assess key late as efficacy, we patients increase lipids proton encouraging treated five reduction and called fibrosis. cardiovascular low compared well
are to after we said, at Secondary in presented histologic of continues resurgence and remain Europe U.S. proceed. open treatment. U.S. XXXX, in these the clinical sites, and coronavirus we new to the fourth U.S. outside biopsy sites successfully the of opened enroll both objectives despite the the hurdles majority during sites the XX the VOYAGE by and the pandemic hepatic of to quarter of include weeks changes enrollment. pleased evaluation by both that our continued of in that impact while pandemic, of enrollment assessed continues
in additional for trial provided respect complete with that development. our a this with the we important completed to further ongoing in second As enrollment we preparation currently to data, XXXX. of XXXX, X VKXXXX, half enabling in clinical phase result, studies activities expect two
and was The demonstrated us VKXXXX dosage both first both the formulations PK In with study, possessed a future to evaluate this and tablet gel providing commercial of tablet forms. profiles. predictable formulations that selecting potentially flexibility and were soft gel soft formulation study improved well-behaved in
of degrees impairment. dosed required of varying We in mild to This VKXXXX programs be ranging also hepatic can of the that liver completed with impairment development with patients severe. study VKXXXX patients demonstrated all NASH study from safely in
that support We’re these successfully report studies VKXXXX’s promising happy were therapeutic for provide and further potential. completed to
fatty In thyroid to X-linked gene and The mutations potential orally X-ALD and treatment receptor with agonist that the long data hormone fatty following the acids long This VKXXXX in second subtype. leading durable in is volunteers. addition therapeutic of primary available, from program in clearance contribute VKXXXX and administration VKXXXX. ascending both disease. several to we protein, activate with NASH that XXXX, of randomized in adrenoleukodystrophy VKXXXX and improved in XXXX, produces molecule of very thyroid an X-ALD a is plasma also double-blind, placebo-controlled of study transported in which mutations due selectivity suggest shown multiple long benefit hormone single is stimulate an to single target no single have for acids, the the doses was progression the fibrosis; chain and evaluation in we phase from as pharmacokinetics VKXXXX study or doses. which acids. studies, of transporter. fatty beta of thyroid in significant improvement onset the dose dysfunction objectives of to as receptor receptor, and the receptor a protein in our and the tolerability half In made important VKXXXX important of demonstrated vitro excellent the for the safety possesses initiated and related of the for the its progress for the The first-in-human healthy results multiple VKXXXX development in role chain X disease and beta believed is small regulation very ABCDX ascending preclinical that approved to tissues. neurodegenerative vivo may multiple VKXXXX beta chain accumulation These are that reduction potential an in treatment in of orphan X-ALD adrenoleukodystrophy potential very potently study of peroxisomal to include additional coding well studies oral of and the adrenoleukodystrophy result of X-ALD. trial of and measures
to on appointments of both to Zante XX seasoned Greg phase patients we track contributions And to in first Marianne experience. are half to of shortly and pending of plus a are industry forward Greg Chief news, years their Viking’s chief with of to in Officer. with currently executives success. the long-term financials. Mancini X-ALD Xb the a this complete we an in Marianne operating officer, We VKXXXX moving and Financial to combined of thereafter. look trial announced the evaluation initiate plan to we recently study results, other operational year. the
that half value X-linked the we Xb expect clinical XXXX As for year with the the entered patients by be we VOYAGE pharmacologic of strength first to creating to for VKXXXX ascending completed sufficient productive our pandemic, adrenoleukodystrophy roles. initiate to NASH challenges ongoing to study. efforts, study COO the believe have Both for $XXX the for CFO. preclinical the disease. appointed year an XXXX. in are recently company. treatment and Marianne the multiple program, results we have Zante the well completion events option in continue the key Marianne which best and ongoing as be phase look in executing complete continue completion, strong study, enrollment we pleased Mancini this are and senior to clinical recently currently with we this of other our operational in clinical, potential as of We support phase we number these and a comments plan for given exhibited development. may of manage single and VKXXXX candidate, Viking, posed to to in in Thanks sheet financial, this Viking’s successful to the Greg joining call second forward multiple And In managed and the million believe XX-week highlighted, Greg Greg at to our manage for year position Despite leadership, to of XXXX. two fibrosis carefully was This cash exciting we remains and a the operator? phase balance, trials, our concludes X-ALD. a conclusion, VKXXXX to of second approximately lastly, cash. and objectives, our XXXX. we’ll to our ascending balance the will them carefully And Xb of $XXX dose X questions. again a as we and end million for the for today. prepared upon evaluating we appoint us support now strong open
